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of antimicrobial agents in determining the epi-
demiology of severe infectious complications
caused by antibiotic-resistant pathogens in cancer
hospitals. There is an overall need for more
judicious use of ﬂuoroquinolones, as these
agents may be important for empirical therapy
(both oral and parenteral) of febrile neutropenia,
especially in the presence of b-lactam allergy, or
for the treatment of severe documented infections
caused by multiresistant Gram-negative bacteria.
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ABSTRACT
The possibility of liver involvement in Mycoplas-
ma pneumoniae pneumonia is still controversial.
This study investigated 33 adult patients with
serologically conﬁrmed M. pneumoniae commu-
nity-acquired pneumonia (CAP) (median age
31 years) and 38 patients with bacteraemic Strep-
tococcus pneumoniae CAP (median age 54 years),
all without pre-existing liver disease. Serum
alanine aminotransferase (ALT) levels were ele-
vated in 12 (36.4%) patients with M. pneumoniae
CAP (median 53.5 U ⁄L), and in four (10.5%)
patients with S. pneumoniae CAP (median 61 U ⁄L)
(p 0.025). In most patients with M. pneumoniae
CAP, the elevated ALT levels decreased during
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macrolide therapy, although this decrease was
not signiﬁcant.
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The association between pneumonia caused by
Mycoplasma pneumoniae and liver damage is con-
troversial [1]. In the present retrospective study,
alanine aminotransferase (ALT) levels were ana-
lysed as a speciﬁc indicator for liver damage in
patients with M. pneumoniae community-acquired
pneumonia (CAP), diagnosed by highly elevated
antibody titres in comparison with an unpaired
serum specimen [2]. In total, 33 patients
(29 inpatients; four outpatients; 13 females; median
age 31 years, range 18–66 years) with M. pneumo-
niae CAP were investigated, of whom 26 were
identiﬁed by a search of the electronic archive
(January 1992 – March 2003) of the Clinical
Division of Virology, Vienna General Hospital,
Austria. An antibody titre of ‡1:256 in a comple-
ment ﬁxation test (Dade Behring, Marburg,
Germany) with M. pneumoniae antigen (Viri-
on ⁄ Serion, Wu¨rzburg, Germany) was chosen as
the cut-off value for diagnosis of M. pneumoniae
infection [2]. In addition, seven patients were
included with antibody titres of ‡1:1250 in a
microparticle agglutination assay (SeroDiaTM
Myco II; Fujirebio, Tokyo, Japan), who had con-
cordant results with different serological assays in
a previous study [3]. The case history of one
patient has been published previously [4]. As a
control group, 38 patients (all hospitalised; 18
females; median age 54 years, range 18–88 years)
with bacteraemic S. pneumoniae CAP diagnosed
by blood culture (VITALTM system; bioMe´rieux,
Marcy L’Etoile, France; incubation for 7 days)
were identiﬁed by a search of the electronic
archive for the same period.
ALT levels were determined by the DGKC
method (Roche Diagnostics, Mannheim,
Germany) using an Hitachi 747 Clinical Analyzer
(Hitachi, Tokyo, Japan). Reference ranges for ALT
were 0–19 U ⁄L (female) and 0–23 U ⁄L (male).
Serum C-reactive protein (CRP; normal range
<1 mg ⁄ 100 mL) levels were determined by
nephelometry (Roche Diagnostics, Mannheim,
Germany) using a Hitachi 747 Clinical Analyzer.
Leukocyte counts (normal range 4.0–10.0 · 103
cells ⁄lL) were determined using an automated
XE-8000 Haematology Analyzer (Sysmex Cor-
poration, Kobe, Japan). Each of these values was
determined within 48 h of CAP diagnosis. A
second ALT determination during convalescence
was reviewed for patients with M. pneumoniae
CAP.
Patients with underlying liver diseases which
cause elevated serum ALT levels (i.e., HBV and
HCV infection, primary or secondary tumours of
the liver, liver cirrhosis and steatosis hepatitis)
were not included in the study. Statistical analysis
was performed by Chi square test using EpiInfo
2002 (CDC, Atlanta, GA, USA) and by the
Wilcoxon Two Sample Test. A p value of <0.05
was considered signiﬁcant.
Serum ALT levels were elevated in 12 (36%)
patients with M. pneumoniae CAP (median
53.5 U ⁄L, range 24–233 U ⁄L). In the S. pneumoniae
group, four (10%) patients had elevated ALT
serum levels (median 61 U ⁄L, range 21–365 U ⁄L)
(p 0.025). Of the 33 patients with M. pneumoniae
CAP, 28 were treated with macrolides, one with
doxycycline, and one with ciproﬂoxacin. Three
patients received no antibiotics active against
M. pneumoniae. Of the 12 patients with M. pneu-
moniae CAP and elevated ALT levels at admis-
sion, ten received macrolides, one received
doxycycline, and one received no antimicrobial
therapy. A second ALT level was available after a
median interval of 9 days (range: 3–15 days) for
11 of the 12 patients with M. pneumoniae CAP and
elevated ALT levels at admission. In seven of
these patients (six of whom were treated with
macrolides), the ALT level decreased, while it
increased in the other four patients (median ALT
change )24 U ⁄L, range )144 to +49 U ⁄L).
A second ALT value was available after a
median interval of 9 days (range 2–25 days) for 19
of the 21 patients with M. pneumoniae CAP and
normal ALT levels at admission. The median ALT
change was +3 (range )6 to +10). The ALT level
increased in 15 patients and decreased in the
remaining four, but the ALT level increased over
the reference range (from 19 to 26 U ⁄L) in only
one patient. The difference between the ALT level
at diagnosis and after treatment was not signiﬁ-
cant for patients with elevated ALT levels at
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admission who received macrolide treatment
(p 0.6911), nor for the six patients with decreased
ALT levels who received macrolide treatment
(p 0.145).
Patients with M. pneumoniae CAP had lower
CRP levels (median 7.8 mg ⁄ 100 mL, range 0.5–
38.5 mg ⁄ 100 mL) than patients with S. pneumoni-
ae pneumonia (median 28.4 mg ⁄ 100 mL, range
0.5–62.2 mg ⁄ 100 mL; p < 0.001). Acute phase leu-
kocyte counts were also lower in theM. pneumoniae
group (median 10.2 · 103 cells ⁄ lL, range
5.1–52.9 · 103 cells ⁄ lL) than in the S. pneumoniae
group (median 16.1 · 103 cells ⁄ lL, range
7.5–42.3 · 103 cells ⁄ lL; p < 0.001). For the latter
calculation, six patients in the S. pneumoniae
group who were leukopenic because of immuno-
suppressive therapy were not included. None of
the patients with M. pneumoniae CAP was
leukopenic.
Patients with M. pneumoniae CAP and elevated
ALT levels showed higher leukocyte counts
(median 13.85 · 103 cells ⁄ lL) than patients with
M. pneumoniae CAP and normal ALT levels
(median 9.7 · 103 cells ⁄ lL, p 0.025). The CRP
levels in patients with M. pneumoniae CAP with
elevated and normal ALT levels, respectively,
were not signiﬁcantly different (median 11.45 vs.
5.89; p 0.23). M. pneumoniae CAP patients with
elevated and normal ALT levels, respectively, did
not differ signiﬁcantly in terms of age (median
age 32 vs. 30 years), or gender distribution (50%
vs. 33% female patients).
Hepatitis associated with mycoplasma pneu-
monia was ﬁrst described in 1975 [5]. Later
studies reported a low prevalence of mycoplas-
ma-associated hepatitis (2–5%), but rates of up to
36% have been reported [6–8]. Cholestatic hepa-
titis has been described as the main or concom-
itant manifestation of mycoplasma infection in
both paediatric and adult patients [9–11]. In
addition, hepatitis has been described in rare
cases of M. pneumoniae-associated multiorgan
failure [12,13], and M. pneumoniae has been
implicated in Kawasaki disease with hepatic
manifestations [14,15]. Reports of histological
examinations of liver biopsies in patients with
mycoplasma-associated hepatitis are rare; a
biopsy revealed non-speciﬁc reactive hepatitis in
one individual [5], whilst massive hepatocellular
destruction and inﬂammatory inﬁltration have
also been observed [12]. Chronic active hepatitis
has also been reported [16].
The possible pathogenetic pathways of
M. pneumoniae-associated liver damage are un-
known. Mechanisms could include direct inva-
sion of the pathogen or immune-mediated
damage. Infection of liver or biliary cells by
M. pneumoniae has never been demonstrated, but
it has been shown that M. pneumoniae uses the
surface-associated pyruvate dehydrogenase to
bind to the extracellular matrix protein ﬁbronec-
tin, which is highly expressed in the liver [10].
The ability of macrolide antibiotics to cause
cholestatic hepatitis is well-known [17,18]. Macro-
lides are used frequently for the treatment of
mycoplasma pneumonia, and should be consid-
ered as an alternative explanation for elevated
serum ALT levels in patients with this disease.
However, most patients in the present study with
M. pneumoniae CAP and elevated serum ALT
levels received macrolides and showed a decrease
in ALT levels during treatment, although this
difference was not signiﬁcant.
In conclusion, the present data suggest that
liver involvement may not be rare in patients with
M. pneumoniae pneumonia. However, additional
studies on a larger scale are required to conﬁrm
this previously described, but still controversial
ﬁnding.
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ABSTRACT
Aqueous and ethanolic extracts of ten traditional
Thai medicinal plants were investigated for their
ability to inhibit 35 hospital isolates of methicillin-
resistant Staphylococcus aureus (MRSA). Nine
medicinal plants displayed activity against all
isolates tested. Ethanolic extracts of Garcinia
mangostana, Punica granatum and Quercus infectoria
were most effective, with MICs for MRSA isolates
of 0.05–0.4, 0.2–0.4 and 0.2–0.4 mg ⁄mL, respect-
ively, and for S. aureus ATCC 25923 of 0.1, 0.2 and
0.1 mg ⁄mL, respectively. MBCs for MRSA iso-
lates were 0.1–0.4, 1.6–3.2 and 0.4–1.6 mg ⁄mL,
and for S. aureus ATCC 25923 were 0.4, 3.2 and
1.6 mg ⁄mL, respectively.
Keywords Antibacterial activity, herbs, medicinal
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The investigation of traditionally used plants for
biologically active extracts has been well-docu-
mented. Recent studies [1–12] have revealed that
medicinal plants from various parts of the world
can provide a rich source of antibacterial activ-
ities. In Thailand, many plant species have been
used widely to cure infectious diseases. Such
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